Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Lateral flow assays industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Application trends
2.1.4 Technique trends
2.1.5 End-use trends
2.1.6 Regional trends
Chapter 3 Lateral Flow Assays Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing prevalence of infectious disease
3.3.1.2 Growing demand for point-of-care testing
3.3.1.3 Technological advancements
3.3.2 Industry pitfalls & challenges
3.3.2.1 Low accuracy of results
3.3.2.2 Availability of substitute product
3.3.2.3 Stringent regulatory framework
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By application
3.4.3 By technique
3.4.4 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6.3 China
3.7 Technology landscape
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard
Chapter 5 Lateral Flow Assays Market, By Product
5.1 Key product trends
5.2 Kits
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Readers
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Lateral Flow Assays Market, By Application
6.1 Key application trends
6.2 Infectious disease testing
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.2.2 Influenza
6.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.2.3 Sexually transmitted disease (STD)
6.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.2.4 Hepatitis
6.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.2.5 Tuberculosis
6.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.2.6 Others
6.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Cardiac marker testing
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.2 Creatine kinase-MB (CK-MB)
6.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.3 Myoglobin
6.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.4 D-dimer
6.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.5 Troponin I
6.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3.6 Others
6.3.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Pregnancy and fertility testing
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4.2 Pregnancy testing
6.4.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4.3 Fertility testing
6.4.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Cholesterol testing
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Drug-of-Abuse (DoA) testing
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Other
6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Lateral Flow Assays Market, By Technique
7.1 Key technique trend
7.2 Sandwich assays
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Competitive assays
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Multiplex detection assays
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Lateral Flow Assays Market, By End-use
8.1 Key end-use trend
8.2 Hospital & clinics
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Diagnostic laboratories
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Homecare settings
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.5 Others
8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Lateral Flow Assays Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Switzerland
9.3.8 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Indonesia
9.4.7 Thailand
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Abingdon Health
10.2 Abbott
10.3 Bio-Rad Laboratories
10.4 Bioeasy Biotechnology Inc.
10.5 bioMerieux SA
10.6 Hologic Inc.
10.7 F. Hoffmann La Roche
10.8 Thermo Fischer Scientific
10.9 OPERON, S.A.
10.10 Quidel Corporation